Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 14/20 | 0.68 |
| ▸ | TMIGD3 | P0DMS9 | 6/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25566698 | 0.86 | ADORA3 (0.57) | ADORA3TMIGD3ADORA1ADORA2AHTR2B | |
| SCHEMBL16774389 | 0.81 | ADORA3 (1.00) | ADORA3TMIGD3ADORA1ADORA2AHTR2B | |
| SCHEMBL22359924 | 0.78 | ADORA3 (0.71) | ADORA3TMIGD3ADORA1 | |
| SCHEMBL25566680 | 0.76 | ADORA3 (0.62) | ADORA3TMIGD3ADORA1ADORA2AADORA2B | |
| SCHEMBL18352618 | 0.76 | ADORA3 (0.84) | ADORA3TMIGD3ADORA1ADORA2AHTR2B | |
| SCHEMBL20122153 | 0.74 | ADORA3 (0.66) | ADORA3TMIGD3ADORA1ADORA2AADORA2B | |
| SCHEMBL16774268 | 0.71 | ADORA3 (1.00) | ADORA3TMIGD3ADORA1ADORA2A | |
| SCHEMBL25566679 | 0.71 | ADORA3 (1.00) | ADORA3TMIGD3ADORA1ADORA2A | |
| SCHEMBL16774388 | 0.71 | ADORA3 (1.00) | ADORA3TMIGD3ADORA1ADORA2A | |
| SCHEMBL22750488 | 0.70 | ADORA3 (0.57) | ADORA3TMIGD3ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023091791-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |